A patient I saw recently had failed four antidepressants over three years, including two augmentation strategies. She was functional, holding a job, maintaining relationships, but living inside what she described as a gray ceiling she could never push through. Within 48 hours of her first ketamine session through our telehealth program, she sent a message saying the ceiling had lifted. Not dissolved, not cured, but lifted enough for her to feel that recovery was a direction she could actually move in. That response pattern is something I have now seen across thousands of patients. What I have not seen, until now, is a meta-analysis large enough to confirm it at the level of evidence the field demands.

A systematic review and meta-analysis published in JAMA Psychiatry analyzed 26 randomized clinical trials enrolling 1,166 patients with a major depressive episode and found that single and repeated intravenous ketamine infusions significantly reduced both depressive and suicidal symptoms in the acute phase. This is not a surprise to anyone treating these patients. What it represents is something more valuable: the evidentiary anchor the field has been waiting for to move the conversation from “is ketamine real?” to “how do we design the next generation of trials correctly?”

The Signal the Trials Confirm

The mechanistic case for ketamine has always been compelling. By antagonizing NMDA receptors and triggering downstream AMPA receptor upregulation and BDNF release, ketamine produces rapid synaptogenesis in prefrontal circuits that conventional monoaminergic antidepressants never touch. That is why the response appears in hours rather than weeks, and why it reaches patients whose illness has been refractory to multiple prior treatment lines. The JAMA Psychiatry findings confirm this mechanism translates to measurable clinical outcomes in controlled conditions across a dataset large enough to draw from.

The broader regulatory arc reinforces the importance of this confirmation. Janssen received FDA Breakthrough Therapy Designation for esketamine in November 2013 for treatment-resistant depression, and again in August 2016 for MDD with imminent suicide risk. Spravato received full FDA approval on March 5, 2019. That approval pathway validated the acute mechanism for treatment-resistant cases. What the JAMA Psychiatry meta-analysis adds is confirmation that the signal holds across broader MDE populations in the acute phase, which matters enormously for how sponsors should be thinking about who belongs in the next trial.

But the meta-analysis also surfaces a limitation the field keeps stepping around. A systematic review from Johns Hopkins examining over 460 blood-based biomarkers, including neurotrophic factors, ketamine metabolite levels, and inflammatory markers across more than 40 studies, found no consistent associations between any biomarker and antidepressant response to ketamine or esketamine. We can confirm the population-level signal. We still cannot predict, at the individual patient level, who will respond.

What 1,166 Patients Cannot Tell You

In my practice, the patients who respond most dramatically to ketamine share characteristics that no current enrollment criterion captures: a specific quality of cognitive rigidity, a history of treatment failure that spans multiple mechanisms, and frequently, a co-occurring substance use history that conventional trial protocols would have excluded them for. That last point is where trial design and clinical reality diverge most sharply.

The durability question is the one I watch most closely. Acute efficacy at 24 to 72 hours is now confirmed. What happens at week six, month three, month twelve, especially in patients without psychotherapy integration, remains the field’s open question. The MUSIK randomized clinical trial, which examined ketamine as a psychedelic-assisted treatment in highly refractory depression with structured music and therapeutic support, is pointing toward integration as a durability lever. Having now treated more than 30,000 patients with guided ketamine therapy through our telehealth network, I see the same pattern: the acute lift is reliable, but the patients who build on it are the ones who have a therapeutic container to work within.

Trial protocols are not designed around that container. They measure response at fixed timepoints using scales that were built for monoaminergic drug trials. The meaningful clinical question (does this patient’s functional trajectory change? does their relationship to their illness change?) rarely appears as a primary endpoint.

The Design Gap the Field Needs to Close

The JAMA Psychiatry meta-analysis confirms acute efficacy across 26 trials. What it cannot confirm is whether those 1,166 patients look anything like the patients who will actually receive ketamine in clinical practice. Dual-diagnosis patients, Spanish-speaking patients enrolled through telehealth, patients with alcohol use disorder and comorbid MDD: these populations are systematically underrepresented in the RCT dataset, yet they represent a substantial share of the real-world disease burden. Enrollment criteria that require clean substance histories are not protecting trial integrity at this point; they are producing an evidentiary base that does not generalize to the patients most in need.

The next generation of ketamine trials should treat biomarker-based patient selection as a primary design objective, given that the Johns Hopkins biomarker review found no reliable predictors after examining hundreds of candidates. Durability endpoints measured at six and twelve months, with psychotherapy integration as an active variable rather than a protocol footnote, would close the gap between what the acute-phase data now confirms and what clinicians actually need to know.

I am watching for the next readout on psychotherapy-integrated ketamine protocols and for any sponsor willing to enroll the dual-diagnosis population the field has been avoiding. That trial, when it arrives, will tell us something the current meta-analysis cannot.

References

  1. JAMA Psychiatry: “Meta-Analysis: Ketamine Injections Rapidly Reduce Major Depressive Episode Symptoms”
  2. PubMed: Systematic review and meta-analysis of 26 RCTs, 1,166 patients with MDE, ketamine acute phase efficacy
  3. Johnson & Johnson: Esketamine FDA Breakthrough Therapy Designation, August 16, 2016
  4. Janssen: FDA Approval of Spravato (esketamine), March 5, 2019
  5. Johns Hopkins: “Blood-Based Biomarkers of Antidepressant Response to Ketamine and Esketamine,” Molecular Psychiatry
  6. British Journal of Psychiatry: MUSIK Randomised Clinical Trial: Ketamine as Psychedelic Treatment for Highly Refractory Depression
+ posts

Dr. Leonardo Vando, MD is Principal Investigator of Psychiatry at Vando Medical Services.